STOCK TITAN
  1. Home
  2. Sec-filings
  3. DRUG
  4. [6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer)

Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. reported that it will present at the Jefferies Global Healthcare Conference on June 3, 2026 at 4:20 p.m. EDT, with a live and archived webcast available through its investor website for 30 days.

The Company also granted stock options to directors, officers and consultants to purchase an aggregate of 109,000 common shares under its share option plan. The options are exercisable at US$83.40 per share for five years and vest in four equal annual installments of 25%, starting on the first anniversary of the grant date.

Positive

  • None.

Negative

  • None.
Stock options granted 109,000 shares Aggregate options granted to directors, officers and consultants
Exercise price US$83.40 per share Option exercise price under share option plan
Option term 5 years Exercise period from date of grant
Vesting schedule 4 installments of 25% Annual vesting starting on first anniversary of grant
Conference date and time June 3, 2026, 4:20 p.m. EDT Jefferies Global Healthcare Conference presentation slot
Webcast replay period 30 days Duration webcast remains accessible on investor website
5-HT2 agonists medical
"developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy"
Drugs described as 5-HT2 agonists are medicines that act like a key fitting into a specific serotonin receptor (the 5-HT2 family) to switch that receptor on. Investors care because turning these receptors on can produce therapeutic effects (for conditions like mood, appetite or sleep) but also carries distinct safety and regulatory risks tied to which 5-HT2 subtype is affected, so trial results and approvals can strongly move a company’s value.
Prader-Willi Syndrome medical
"for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression"
A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.
central nervous system (CNS) disorders medical
"depression, and other central nervous system (CNS) disorders"
share option plan financial
"pursuant to the Company's share option plan"
serotonergic agonists medical
"a unique platform of highly selective serotonergic agonists exhibiting selectivity"
Serotonergic agonists are drugs or compounds that activate the brain’s serotonin receptors, acting like keys that turn on specific cellular “locks” involved in mood, sleep, pain, and other bodily functions. Investors watch them because their ability to treat common or hard-to-treat conditions can create large markets, raise regulatory and safety questions, and affect a drug maker’s revenue and valuation depending on clinical trial results, approvals, patents and side-effect profiles.
NCE programs medical
"a rich portfolio of NCE programs within neurology and psychiatry"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Bright Minds Biosciences (DRUG) announce in this Form 6-K?

Bright Minds Biosciences announced a presentation at the Jefferies Global Healthcare Conference and the grant of stock options for 109,000 common shares. The options were granted to directors, officers and consultants under its share option plan at a set exercise price.

When will Bright Minds Biosciences (DRUG) present at the Jefferies Global Healthcare Conference?

Bright Minds will present on Wednesday, June 3, 2026 at 4:20 p.m. EDT. The presentation will be available via live webcast, with an archived replay accessible for 30 days through the company’s investor relations website.

How many stock options did Bright Minds Biosciences (DRUG) grant and to whom?

The company granted options to purchase an aggregate of 109,000 common shares. These options were awarded to certain directors, officers and consultants of Bright Minds under its established share option plan as part of its equity compensation program.

What are the key terms of the new stock options granted by Bright Minds (DRUG)?

The options are exercisable at US$83.40 per share for five years from the grant date. They vest in four equal annual installments of 25% each, beginning on the first anniversary of the grant, aligning compensation with longer-term company performance.

Where can investors access the Bright Minds (DRUG) conference webcast?

Investors can access the live and archived webcast via the Bright Minds investor relations website, under the Events and Presentation section. The replay of the Jefferies Global Healthcare Conference presentation will remain available for 30 days.

What therapeutic areas is Bright Minds Biosciences (DRUG) focused on?

Bright Minds develops therapies for neurological and psychiatric disorders, including drug-resistant epilepsy, Prader-Willi Syndrome, depression and other CNS disorders. Its pipeline centers on highly selective serotonergic agonists targeting key brain receptors to address high unmet medical needs.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

 

400 N Aberdeen St Suite 900
Chicago, IL 60642
(U.S. Corporate headquarters)

1122 Mainland St #228
Vancouver, BC V6B 5L1
(Canadian Corporate headquarters)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ ]  Form 40-F  [ X ]

 

 

SUBMITTED HEREWITH

 

 

Exhibits

 

99.1

News Release dated May 26, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BRIGHT MINDS BIOSCIENCES INC.

 

/s/ Ryan Cheung  

Ryan Cheung
Chief Financial Officer

Date: May 27, 2026

FOR IMMEDIATE RELEASE

 

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

 

New York City –  May 26, 2026 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

 

DATE: Wednesday, June 3, 2026 

TIME: 4:20PM EDT  

WEBCAST:https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/bvVWVgeHmHjUbuFuDEjCS8 

 

The live and archived webcast will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 30 days.

Bright Minds further releases that the Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate of 109,000 common shares in the capital of the Company (the “Shares”) pursuant to the Company's share option plan. The Options are exercisable at a price of US$83.40 per Share for a period of five (5) years from the date of grant. The Options vest in four (4) equal annual instalments of 25% each, commencing on the first anniversary of the date of grant.

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

 

Alex Vasilkevich

Chief Operating Officer

Bright Minds Biosciences Inc.

T: 414-731-6422

E: alex@brightmindsbio.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases